Summary - Recent progress in fetal medicine;Quoi de neuf en médecine fœtale ?

Archives de Pediatrie

Volumn 9, Issue 2, 2002, Pages 172-186

  Mahieu Caputo, D ^a,f   Senat, M V ^c   Romana, S ^d   Houfflin Debarge, V ^e   Gosset, P ^d   Audibert, F ^b   Bessis, R ^d   Ville, Y ^c   Vekemans, M ^d   Dommergues, M ^d  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Cytogenetics; Fetal medicine; Prenatal diagnosis; Ultrasonography, prenatal

Indexed keywords

ANGIOTENSIN; RENIN;

AUTOPSY; BLOOD ANALYSIS; BLOOD SAMPLING; CHROMOSOME ABERRATION; CLINICAL PRACTICE; CYTOGENETICS; DIAGNOSTIC VALUE; DNA DETERMINATION; DOWN SYNDROME; EARLY DIAGNOSIS; ECHOGRAPHY; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LASER COAGULATION; MATERNAL AGE; MATERNAL BLOOD; PERINATAL CARE; PRENATAL DIAGNOSIS; QUALITY CONTROL; RADIODIAGNOSIS; REVIEW; SCREENING; SECOND TRIMESTER PREGNANCY; SEX DETERMINATION; TREATMENT INDICATION; TWIN TWIN TRANSFUSION SYNDROME;

EID: 0036186428     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0929-693x(01)00728-x     Document Type: Review

References (101)

1. Antenatal screening for Down's syndrome
2. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation
3. Increased nuchal translucency as a marker for fetal chromosomal defects
4. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population
5. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice
6. Screening of maternal serum for fetal Down's syndrome in the first trimester
7. Effect of first trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome
8. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome
9. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters
10. Efficiency of ultrasound and biochemical markers for Down's syndrome risk screening. A prospective study
11. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: A prospective longitudinal study
12. Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers
13. New Down syndrome screening algorithm: Ultrasonographic biometry and multiple serum markers combined with maternal age
14. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A
15. Berger R (12 ; 21): A new recurrent translocation in acute lymphoblastic leukemia
16. Ten Kate LP Rapid detection of microdeletions using fluorescence in situ hybridisation (FISH) on buccal smears
17. The Pallister-Killian syndrome is reliably diagnosed by FISH on buccal mucosa
18. Mosaic unbalanced structural abnormalities confirmed using FISH on buccal mucosal cells
19. Preimplantation genetic analysis of translocations: Case-specific probes for interphase cell analysis
20. Rapid detection of chromosome aneuploidies in uncultured amniocytes by using fluorescence in situ hybridization (FISH)
21. Multicolor fluorescence in situ hybridization for the simultaneous detection of probe sets for chromosomes 13, 18, 21, X and Y in uncultured amniotic fluid cells
22. A simple method for prenatal diagnosis of trisomy 21 on uncultured amniocytes
23. Rapid prenatal diagnosis of chromosomal aneuploidies by fluorescence in situ hybridization: Clinical experience with 4,500 specimens
24. Perfect endings: A review of subtelomeric probes and their use in clinical diagnosis
25. CGH in mentally retarded patients with dysmorphic features and normal karyotype
26. Genomic disorders: Structural features of the genome can lead to DNA rearrangements and human disease traits
27. Masquerading repeats: Paralogous pitfalls of the human genome
28. Pathological consequences of sequence duplications in the human genome
29. Structure of chromosomal duplicons and their role in mediating human genome disorders
30. The DNA sequence of human chromosome 22
31. Karyotyping human chromosomes by combinatorial multi-fluor FISH
32. Multicolor spectral karyotyping of human chromosomes
33. Spectral karyotyping and multicolor fluorescence in situ hybridization reveal new tumor-specific chromosomal aberrations
34. Reassessment of childhood B-lineage lymphoblastic leukemia karyotypes using spectral analysis
35. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors
36. Minimal sizes of deletions detected by comparative genomic hybridization
37. Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe
38. Comparative genomic hybridization: Uses and limitations
39. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays
40. Matrix-based comparative genomic hybridization: Biochips to screen for genomic imbalances
41. Fetal cells in maternal circulation throughout gestation
42. Fetal cells in the maternal circulation during first trimester in pregnancies
43. Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis
44. Fetal cells in the mother: From genetic diagnosis to diseases associated with fetal cell microchimerism
45. Isolation of fetal DNA from nucleated erythrocytes in maternal blood
46. Isolating fetal cells from maternal blood: Advances in prenatal diagnosis through molecular technology
47. Fetal nucleated cells in maternal peripheral blood: Frequency and relationship to gestational age
48. Non invasive prenatal diagnosis using fetal cells in maternal blood
49. Prenatal genetic diagnosis by isolation and analysis of fetal cells circulating in maternal blood
50. Prenatal diagnosis by analysis of fetal cells in maternal blood
51. Development of non invasive fetal DNA diagnosis from maternal blood
52. First trimester prenatal diagnosis of trisomy 21 in fetal cells from maternal blood
53. Prenatal diagnosis of fetal hemoglobin Lepore - Boston disease on maternal peripheral blood
54. Fetal RhD genotyping in fetal cells flow sorted from maternal blood
55. Detection of paternally inherated mutations for beta thalassemia in trophoblast isolated from peripheral maternal blood
56. Culture of fetal erythroid cells from maternal peripheral blood
57. Detection of fetal RHD-specific sequences in maternal plasma
58. Genotyping fetal DNA by non invasive means: Extraction from maternal plasma
59. Multiplex and real-time quantitative PCR on fetal DNA in maternal plasma. A comparison with fetal cells isolated from maternal blood
60. High sensitivity of fetal DNA in plasma compared to serum and nucleated cells using unnested PCR in maternal blood
61. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma
62. Fetal DNA in maternal plasma: The prenatal detection of a paternally inherited fetal aneuploidy
63. Therapeutic amniocentesis in twin-twin transfusion syndrome appearing in the second trimester of pregnancy
64. Preliminary experience with endoscopic laser surgery for severe twin-twin transfusion syndrome
65. Reduction in the middle cerebral artery pulsatility index after decompression of polyhydramnios in twin gestation
66. Treatment of twin twin transfusion syndrome
67. The stuck twin phenomenon: Ultrasonographic findings, pregnancy outcome and management with serial amniocenteses
68. Stuck twin syndrome: Outcome in thirty-seven consecutive cases
69. Antepartum and postpartum complications of twin-twin transfusion
70. Serial amniocentesis in the management of twin-twin transfusion syndrome: When is it valuable?
71. Endoscopic laser surgery versus serial amniocenteses in the treatment of severe twin-twin transfusion syndrome
72. Agressive therapeutic amniocentesis for treatment of twin-twin transfusion syndrome
73. Long-term outcome in twin-twin transfusion syndrome treated with serial aggressive amnioreduction
74. Amniotic septostomy for the treatment of twin oligohyframnios-polyhydramnios sequence
75. Failure of amniotic septostomy in the management of 3 subsequent cases of severe previable twin-twin transfusion syndrome
76. Iatrogenic monoamniotic twin gestation with progressive twin-twin transfusion syndrome
77. Iatrogenic creation of a monoanmiotic twin gestation in severe twin-to-twin transfusion syndrome
78. Amniotomy: A new approach to the stuck twin syndrome
79. Amniotic fluid pressure in both cavities of twin-to-twin transfusion syndrome: A vote against septostomy
80. Endoscopic laser coagulation in the management of severe twin-to-twin transfusion syndrome
81. Angioarchitecture of monochorionic placentas in relation to the twin-twin transfusion syndrome
82. Placental angioarchitecture in monochorionic twin pregnancies: Relationship to fetal growth, fetofetal transfusion syndrome, and pregnancy outcome
83. Correlations of placental vascular anatomy and clinical outcomes in 69 monochorionic twin pregnancies
84. Haematological indices at fetal blood sampling in monochorionic pregnancies complicated by feto-fetal transfusion syndrome
85. Pathogenesis of twin-twin transfusion syndrome: The renin-angiotensin system hypothesis
86. Pathophysiology of polyhydramnios in twin transfusion syndrome
87. Comparison of intrauterine hematologic and biochemical values between twin pairs with and without stuck twin syndrome
88. Fetal origins of reduced arterial distensibility in the donor twin in twin-twin transfusion syndrome
89. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification
90. Preimplantation genetic diagnosis: Strategies and surprises
91. Preimplantation genetic diagnosis (PGD)
92. First specific preimplantation genetic diagnosis for ornithine transcarbamylase deficiency
93. Chromosome translocations: Segregation modes and strategies for preimplantation genetic diagnosis
94. Le diagnostic pré-implantatoire (DPI) en France: Bilan d'activité du Groupe d'Étude et de Travail du Diagnostic Pré-Implantatoire (GET-DPI) année 2000
95. ESHRE Preimplantation Genetic Diagnosis (PGD) Consortium: Preliminary assessment of data from January 1997 to September 1998
96. ESHRE preimplantation genetic diagnosis (PGD) consortium: Data collection II (May)
97. Diagnostic génétique préimplantatoire: Techniques et résultats
98. Eugénisme
99. In the light of preimplantation genetic diagnosis: Some ethical issues in medical genetics revisited